International Isotopes posts results

Article

Radiopharmaceutical manufacturer International Isotopes last month posted its fiscal 1998 results (end-December). The Denton, TX, firm reported revenues of $2 million for the year, a dramatic increase over 1997’s $136,000. The company attributed the

Radiopharmaceutical manufacturer International Isotopes last month posted its fiscal 1998 results (end-December). The Denton, TX, firm reported revenues of $2 million for the year, a dramatic increase over 1997’s $136,000. The company attributed the increase to its International Isotopes Idaho subsidiary’s product sales, as well as income from development contracts. The company’s net loss for the year was $5.5 million, compared with the previous year’s $4.4 million loss.

In other news, the firm last month formed a joint venture with GammaPlus, an Austin, TX-based subsidiary of Lucas Medical Associates that operates short-lived radiopharmaceutical manufacturing centers. The joint venture will be called GammaPlus DFW, and will manufacture and distribute PET radiopharmaceuticals, including fluorodeoxyglucose F-18 (FDG). GammaPlus DFW will produce FDG with International Isotopes’ cyclotron, and expects to begin distributing the isotope within the next few months, according to Carl Seidel, president and CEO of International Isotopes. Distribution will be primarily to hospitals and clinics in the Dallas/Fort Worth area, Seidel said.

Recent Videos
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
Related Content
© 2025 MJH Life Sciences

All rights reserved.